強心剤の世界市場レポート 2025年

強心剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12.6％で50億6,000万米ドルに成長します。予測期間の成長は、心血管系死亡率の増加、強心製剤の強化に焦点を当てた臨床試験の増加、心血管系薬剤開発における官民協力の拡大、心臓合併症に関連する入院の増加、個別化心血管系医療に対する需要の高まりに起因すると考えられます。予測期間中の主な動向としては、ペプチドベースの開発、デュアルメカニズム薬の創出、薬理ゲノミクスの統合、注射用デポ製剤の革新、併用療法の進展などが挙げられます。

心血管疾患の有病率の増加は、今後数年間の強心剤市場の成長を促進すると予想されます。心血管疾患（CVD）には、冠動脈疾患、心不全、不整脈、脳卒中など、心臓や血管に影響を及ぼす疾患群が含まれます。この増加は、飽和脂肪酸、トランス脂肪酸、塩分、糖分を多く含む不健康な食生活が主な原因であり、肥満、高血圧、コレステロール値の上昇の一因となっています。強心剤は、心筋の効率と収縮力を高めることで、血液循環を改善し、さまざまな心血管系疾患の症状を緩和します。例えば、2023年12月、オーストラリアの政府機関であるオーストラリア保健福祉研究所は、冠動脈性心疾患（CHD）による医師認定の死亡者数が2021年の1万4,100人から2022年には1万4,900人に増加したと報告しました。その結果、心血管疾患の有病率の上昇が強心剤市場の成長に寄与しています。

強心剤市場の主要企業は、急性心不全や心原性ショックの心機能改善を目的とした短期強心剤などの革新的な製品を開発しています。短期強心剤は、心臓の収縮力を一時的に高め、心拍出量を増加させるために使用されます。例えば、2023年6月、英国の製薬会社Hikma Pharmaceuticals plcは、250mg/20mLバイアル入りのドブタミン注射液、USPを発売しました。この注射液は、心臓疾患や心臓手術後に起こることが多い、心臓収縮力の低下による心筋脱落に苦しむ成人に、短期間の強心作用を提供します。ドブタミンはβ1受容体を刺激し、心筋収縮力と心拍出量を1～2分の速さで増加させます。この注射は静脈内に投与され、通常、病院内で厳重な医学的管理のもとに使用されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の強心剤のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の強心剤市場：成長率分析
• 世界の強心剤市場の実績：規模と成長、2019～2024年
• 世界の強心剤市場の予測：規模と成長、2024～2029年、2034年
• 世界の強心剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の強心剤市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジギタリス配糖体
• ホスホジエステラーゼ阻害剤
• 心臓保護剤
• 交感神経刺激薬
• その他
• 世界の強心剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• その他
• 世界の強心剤市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• 溶液
• その他
• 世界の強心剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 心臓外科手術
• 心房細動
• 心不全
• 肺高血圧症
• その他
• 世界の強心剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の強心剤市場：ジギタリス配糖体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジゴキシン
• ジギトキシン
• ラナトシドC
• 世界の強心剤市場：ホスホジエステラーゼ阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ミルリノン
• エノキシモン
• アムリノン
• 世界の強心剤市場：心臓保護剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コエンザイムQ10
• デクスラゾキサン
• トリメタジジン
• 世界の強心剤市場：交感神経刺激薬のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ドブタミン
• ドーパミン
• ノルエピネフリン
• 世界の強心剤市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• レボシメンダン
• オメカムティブメカルビル
• シロスタゾール

第7章 地域別・国別分析

• 世界の強心剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の強心剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強心剤市場：競合情勢
• 強心剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Fresenius Kabi
• Aurobindo Pharma Limited
• Hikma Pharmaceuticals PLC
• Alchem International Private Ltd
• Farbe Firma Private Limited
• Salius Pharma Pvt. Ltd.
• Johnlee Pharmaceuticals Pvt. Ltd.
• Healthy Life Pharma Pvt Ltd
• Anwita Drugs
• Varion Lifesciences
• Deccan Nutraceuticals Pvt. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 強心剤市場2029年：新たな機会を提供する国
• 強心剤市場2029年：新たな機会を提供するセグメント
• 強心剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cardiotonic agents are a group of drugs that enhance the strength and efficiency of heart muscle contractions, thereby improving the heart's ability to pump blood. These medications are primarily used to manage heart failure and certain arrhythmias by boosting cardiac output and enhancing blood circulation.

The main categories of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds extracted from the Digitalis plant, used to treat heart conditions by increasing contraction force and regulating heart rhythm. These drugs can be administered orally, intravenously, or via other methods, with common dosage forms including tablets and solutions. They are utilized in a variety of clinical scenarios such as cardiac surgeries, atrial fibrillation, heart failure, pulmonary hypertension, among others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The cardiotonic agents market research report is one of a series of new reports from The Business Research Company that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiotonic agents market size has grown rapidly in recent years. It will grow from $2.78 billion in 2024 to $3.14 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the rising prevalence of heart failure, an expanding elderly population, an increasing incidence of coronary artery disease, greater adoption of sedentary lifestyles, and the growing burden of hypertension and diabetes.

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing cardiovascular mortality rates, a rise in clinical trials focused on enhanced cardiotonic formulations, expanding public-private collaborations in cardiovascular drug development, growing hospital admissions related to cardiac complications, and heightened demand for personalized cardiovascular medicine. Key trends during the forecast period include the development of peptide-based cardiotonic agents, creation of dual-mechanism drugs, integration of pharmacogenomics, innovation in injectable depot formulations, and advancement of combination therapies.

The increasing prevalence of cardiovascular diseases is expected to drive growth in the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) include a group of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets rich in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents work by enhancing the heart muscle's efficiency and contraction strength, thereby supporting improved blood circulation and alleviating symptoms in various cardiovascular conditions. For example, in December 2023, the Australian Institute of Health and Welfare, an Australian government agency, reported that doctor-certified deaths due to coronary heart disease (CHD) increased from 14,100 in 2021 to 14,900 in 2022. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the cardiotonic agents market.

Leading companies in the cardiotonic agents market are developing innovative products, including short-term inotropic drugs, aimed at improving cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs are used to temporarily increase the heart's contractility, which enhances cardiac output. For instance, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection provides short-term inotropic support for adults suffering from cardiac decompensation due to reduced heart contractility, often caused by heart disease or following cardiac surgery. Dobutamine stimulates beta-1 receptors to boost heart muscle contractility and cardiac output with a rapid onset of 1 to 2 minutes. The injection is administered intravenously and is typically used in hospital settings under close medical supervision.

In April 2023, SK Capital Partners LP, a US-based capital market company, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed sum. This acquisition aims to accelerate Apotex's growth and innovation by leveraging SK Capital's expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent marketed under the brand name Apo-Digoxin.

Major players in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, and Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the cardiotonic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cardiotonic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cardiotonic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cardiotonic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cardiotonic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiotonic agents market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Digitalis Glycosides; Phosphodiesterase Inhibitors; Cardioprotectants; Sympathomimetic Agents; Other Drug Types
• 2) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
• 3) By Dosage Form: Tablet; Solution; Other Dosage Forms
• 4) By Application: Cardiac Surgical Procedures; Atrial Fibrillation; Heart Failure; Pulmonary Hypertension; Other Applications
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Digitalis Glycoside: Digoxin; Digitoxin; Lanatoside C
• 2) By Phosphodiesterase Inhibitors: Milrinone; Enoximone; Amrinone
• 3) By Cardioprotectants: Coenzyme Q10; Dexrazoxane; Trimetazidine
• 4) By Sympathomimetic Agents: Dobutamine; Dopamine; Norepinephrine
• 5) By Other Drug Types: Levosimendan; Omecamtiv Mecarbil; Cilostazol
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cardiotonic Agents Market Characteristics

3. Cardiotonic Agents Market Trends And Strategies

4. Cardiotonic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cardiotonic Agents Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cardiotonic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cardiotonic Agents Market Growth Rate Analysis
• 5.4. Global Cardiotonic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cardiotonic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cardiotonic Agents Total Addressable Market (TAM)

6. Cardiotonic Agents Market Segmentation

• 6.1. Global Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Digitalis Glycosides
• Phosphodiesterase Inhibitors
• Cardioprotectants
• Sympathomimetic Agents
• Other Drug Types
• 6.2. Global Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Route Of Administrations
• 6.3. Global Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Solution
• Other Dosage Forms
• 6.4. Global Cardiotonic Agents Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Surgical Procedures
• Atrial Fibrillation
• Heart Failure
• Pulmonary Hypertension
• Other Applications
• 6.5. Global Cardiotonic Agents Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Cardiotonic Agents Market, Sub-Segmentation Of Digitalis Glycosides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Digoxin
• Digitoxin
• Lanatoside C
• 6.7. Global Cardiotonic Agents Market, Sub-Segmentation Of Phosphodiesterase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Milrinone
• Enoximone
• Amrinone
• 6.8. Global Cardiotonic Agents Market, Sub-Segmentation Of Cardioprotectants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Coenzyme Q10
• Dexrazoxane
• Trimetazidine
• 6.9. Global Cardiotonic Agents Market, Sub-Segmentation Of Sympathomimetic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dobutamine
• Dopamine
• Norepinephrine
• 6.10. Global Cardiotonic Agents Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Levosimendan
• Omecamtiv Mecarbil
• Cilostazol

7. Cardiotonic Agents Market Regional And Country Analysis

• 7.1. Global Cardiotonic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cardiotonic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cardiotonic Agents Market

• 8.1. Asia-Pacific Cardiotonic Agents Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cardiotonic Agents Market

• 9.1. China Cardiotonic Agents Market Overview
• 9.2. China Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cardiotonic Agents Market

• 10.1. India Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cardiotonic Agents Market

• 11.1. Japan Cardiotonic Agents Market Overview
• 11.2. Japan Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cardiotonic Agents Market

• 12.1. Australia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cardiotonic Agents Market

• 13.1. Indonesia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cardiotonic Agents Market

• 14.1. South Korea Cardiotonic Agents Market Overview
• 14.2. South Korea Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cardiotonic Agents Market

• 15.1. Western Europe Cardiotonic Agents Market Overview
• 15.2. Western Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cardiotonic Agents Market

• 16.1. UK Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cardiotonic Agents Market

• 17.1. Germany Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cardiotonic Agents Market

• 18.1. France Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cardiotonic Agents Market

• 19.1. Italy Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cardiotonic Agents Market

• 20.1. Spain Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cardiotonic Agents Market

• 21.1. Eastern Europe Cardiotonic Agents Market Overview
• 21.2. Eastern Europe Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cardiotonic Agents Market

• 22.1. Russia Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cardiotonic Agents Market

• 23.1. North America Cardiotonic Agents Market Overview
• 23.2. North America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cardiotonic Agents Market

• 24.1. USA Cardiotonic Agents Market Overview
• 24.2. USA Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cardiotonic Agents Market

• 25.1. Canada Cardiotonic Agents Market Overview
• 25.2. Canada Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cardiotonic Agents Market

• 26.1. South America Cardiotonic Agents Market Overview
• 26.2. South America Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cardiotonic Agents Market

• 27.1. Brazil Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cardiotonic Agents Market

• 28.1. Middle East Cardiotonic Agents Market Overview
• 28.2. Middle East Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cardiotonic Agents Market

• 29.1. Africa Cardiotonic Agents Market Overview
• 29.2. Africa Cardiotonic Agents Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cardiotonic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cardiotonic Agents Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cardiotonic Agents Market Competitive Landscape And Company Profiles

• 30.1. Cardiotonic Agents Market Competitive Landscape
• 30.2. Cardiotonic Agents Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Cardiotonic Agents Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. Eli Lilly and Company
• 31.5. Fresenius Kabi
• 31.6. Aurobindo Pharma Limited
• 31.7. Hikma Pharmaceuticals PLC
• 31.8. Alchem International Private Ltd
• 31.9. Farbe Firma Private Limited
• 31.10. Salius Pharma Pvt. Ltd.
• 31.11. Johnlee Pharmaceuticals Pvt. Ltd.
• 31.12. Healthy Life Pharma Pvt Ltd
• 31.13. Anwita Drugs
• 31.14. Varion Lifesciences
• 31.15. Deccan Nutraceuticals Pvt. Ltd

32. Global Cardiotonic Agents Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cardiotonic Agents Market

34. Recent Developments In The Cardiotonic Agents Market

35. Cardiotonic Agents Market High Potential Countries, Segments and Strategies

• 35.1 Cardiotonic Agents Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cardiotonic Agents Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cardiotonic Agents Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer